Toward Engineering Chiral Rodlike Metal-Organic Frameworks with Rare Topologies

The establishment of novel design strategies to target chiral rodlike MOFs, elusively faced until now, is one of the most straightforward manners to widen the scope of MOFs. Here we describe our last advances on the application of the metalloligand design strategy toward the development of efficient routes to obtain chiral rodlike MOFs. To this end, we have used as precursor an enantiopure homochiral hexanuclear wheel (1), derived from the amino acid d-valine, which, after a supramolecular reorganization into a one-dimensional homochiral chain-with the same configuration as 1-led to the formation of a homochiral rodlike MOF (2) exhibiting rare etd topology

Synthesis of Densely Packaged, Ultrasmall Pt02Clusters within a Thioether-Functionalized MOF: Catalytic Activity in Industrial Reactions at Low Temperature

The gram\u2010scale synthesis, stabilization, and characterization of well\u2010defined ultrasmall subnanometric catalytic clusters on solids is a challenge. The chemical synthesis and X\u2010ray snapshots of Pt02 clusters, homogenously distributed and densely packaged within the channels of a metal\u2013organic framework, is presented. This hybrid material catalyzes efficiently, and even more importantly from an economic and environmental viewpoint, at low temperature (25 to 140\u2009\ub0C), energetically costly industrial reactions in the gas phase such as HCN production, CO2 methanation, and alkene hydrogenations. These results open the way for the design of precisely defined catalytically active ultrasmall metal clusters in solids for technically easier, cheaper, and dramatically less\u2010dangerous industrial reactions

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade 653 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design

Clústeres metálicos subnanométricos confinados en redes metalorgánicas como catalizadores para la síntesis de cicloheptatrienos y derivados

La presente invención se refiere a un material híbrido que comprende un MOF de cobre y níquel con ligandos oxamato {IMAGEN-01} que contiene clústeres metálicos subnanométricos, preferentemente de menos de 7 átomos, confinados en los canales del MOF, a su procedimiento de obtención y a su uso como catalizador en la formación de compuestos de mayor valor añadido, por ejemplo cicloheptatrienos.Peer reviewedUniversitat de València, Universitat Politècnica de València, Consejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic